Hansoh Pharmaceutical Group (SHSC:3692) - Aandelenkoers, Nieuws & Analyse

3692 Overzicht aandelen

Hansoh Pharmaceutical Group Company Limited, een investeringsholding, houdt zich bezig met onderzoek, ontwikkeling, productie en verkoop van farmaceutische producten in de Volksrepubliek China. Meer informatie

3692 fundamentele analyse
Sneeuwvlok Score
Waardering	3/6
Toekomstige groei	1/6
Prestaties in het verleden	5/6
Financiële gezondheid	5/6
Dividenden	2/6

Beloningen

Verhandeld tegen 36.5% onder onze schatting van de reële waarde

De winst zal naar verwachting met 2.66% per jaar groeien

De winst groeide het afgelopen jaar met 83.1%

Analisten zijn het erover eens dat de aandelenkoers met 35% zal stijgen

Risicoanalyse

Aanzienlijke insider-verkoop in de afgelopen 3 maanden

Hansoh Pharmaceutical Group Company Limited Concurrenten

CSPC Pharmaceutical Group

SEHK:1093

HK$60.3b

Sino Biopharmaceutical

SEHK:1177

HK$59.5b

China Resources Pharmaceutical Group

SEHK:3320

HK$34.1b

China Medical System Holdings

SEHK:867

HK$18.6b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Hansoh Pharmaceutical Group
Historische aandelenkoersen
Huidige aandelenkoers	HK$17.16
52 Week Hoogtepunt	HK$22.80
52 Week Laag	HK$11.18
Bèta	0.65
11 maand verandering	-22.18%
3 maanden verandering	-6.54%
1 Jaar Verandering	17.37%
33 jaar verandering	-1.94%
5 jaar verandering	-32.57%
Verandering sinds IPO	-31.08%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	3692	HK Pharmaceuticals	HK Markt
7D	-1.3%	-2.1%	0.05%
1Y	17.4%	-9.4%	11.5%

Rendement versus industrie: 3692 overtrof de Hong Kong Pharmaceuticals industrie, die het afgelopen jaar een rendement -9.4 % opleverde.

Rendement versus markt: 3692 overtrof de Hong Kong markt, die het afgelopen jaar een rendement opleverde van 11.5 %.

Prijsvolatiliteit

Is 3692's price volatile compared to industry and market?
3692 volatility
3692 Average Weekly Movement	7.6%
Pharmaceuticals Industry Average Movement	6.9%
Market Average Movement	9.0%
10% most volatile stocks in HK Market	18.9%
10% least volatile stocks in HK Market	4.2%

Stabiele aandelenkoers: 3692 heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 8% ) van 3692 is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1995	9,099	Huijuan Zhong	www.hspharm.com

Hansoh Pharmaceutical Group Company Limited, een investeringsmaatschappij, houdt zich bezig met onderzoek, ontwikkeling, productie en verkoop van farmaceutische producten in de Volksrepubliek China. Het bedrijf levert producten voor therapeutische gebieden, waaronder tumorbestrijding, infectiebestrijding, ziekten van het centrale zenuwstelsel, oncologie, stofwisselingsziekten en auto-immuunziekten, enz. De belangrijkste producten zijn Ameile, Hansoh Xinfu, Pulaile, Zefei, Xintai, Xinmei, Gainuo, Hengmu, Mailingda, Hengsen, XINYUE, Saint Luolai, Fulaimei, Pulaitan, Tanneng, Ameining, Oulanning, Ruibote, Fulaidi, Fulairui en Puruian tabletten.

Hansoh Pharmaceutical Group Company Limited Samenvatting

Hoe verhouden de winst en inkomsten van Hansoh Pharmaceutical Group zich tot de beurswaarde?
3692 fundamentele statistieken
Marktkapitalisatie	HK$101.83b
Inkomsten(TTM)	HK$5.07b
Inkomsten(TTM)	HK$13.01b

20.1x

Koers/Winstverhouding

7.8x

P/S-verhouding

Is 3692 overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
3692 resultatenrekening (TTM)
Inkomsten	CN¥12.10b
Kosten van inkomsten	CN¥1.09b
Brutowinst	CN¥11.01b
Overige uitgaven	CN¥6.30b
Inkomsten	CN¥4.71b

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	0.79
Brutomarge	91.01%
Nettowinstmarge	38.97%
Schuld/Eigen Vermogen Verhouding	0.1%

Hoe presteerde 3692 op de lange termijn?

Bekijk historische prestaties en vergelijking

Dividenden

2.3%

Huidig dividendrendement

40%

Uitbetalingsratio

3692 Overzicht aandelen

Beloningen

Risicoanalyse

Hansoh Pharmaceutical Group Company Limited Concurrenten

SEHK:1093

HK$60.3b

SEHK:1177

HK$59.5b

SEHK:3320

HK$34.1b

SEHK:867

HK$18.6b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Hansoh Pharmaceutical Group Company Limited Announces the NMPA Has Granted Breakthrough-Therapy-Designated Drug for B7-H3-Targeted Antibody-Drug Conjugate HS-20093

Hansoh Pharmaceutical Group Company Limited Announces Phase III Registrational Trial AENEAS2 Evaluating Ameile in Combination with Chemotherapy for Patients with Locally Advanced or Metastatic EGFR-Mutated NSCLC

New major risk - Revenue and earnings growth

First half 2024 earnings released: EPS: CN¥0.46 (vs CN¥0.22 in 1H 2023)

Upcoming dividend of HK$0.20 per share

First half dividend of HK$0.20 announced

Recent updates

Hansoh Pharmaceutical Group Company Limited Announces the NMPA Has Granted Breakthrough-Therapy-Designated Drug for B7-H3-Targeted Antibody-Drug Conjugate HS-20093

Hansoh Pharmaceutical Group Company Limited Announces Phase III Registrational Trial AENEAS2 Evaluating Ameile in Combination with Chemotherapy for Patients with Locally Advanced or Metastatic EGFR-Mutated NSCLC

New major risk - Revenue and earnings growth

First half 2024 earnings released: EPS: CN¥0.46 (vs CN¥0.22 in 1H 2023)

Upcoming dividend of HK$0.20 per share

First half dividend of HK$0.20 announced

New major risk - Revenue and earnings growth

First half 2024 earnings released: EPS: CN¥0.46 (vs CN¥0.22 in 1H 2023)

Hansoh Pharmaceutical Group Company Limited Announces an Interim Dividend for the Six Months Ended June 30, 2024, Payable on 30 October 2024

Hansoh Pharmaceutical Group Company Limited to Report First Half, 2024 Results on Aug 27, 2024

Now 22% undervalued after recent price drop

Hansoh Pharmaceutical Group Company Limited Announces New Drug Application of Ammeile for the Adjuvant Treatment of Egfr Mutation-Positive Non-Small Cell Lung Cancer Accepted by the National Medical Products Administration of the People's Republic of China

Now 22% undervalued

Upcoming dividend of HK$0.14 per share

Now 21% undervalued

Full year 2023 earnings released: EPS: CN¥0.55 (vs CN¥0.44 in FY 2022)

Hansoh Pharmaceutical Group Company Limited, Annual General Meeting, Jun 13, 2024

Hansoh Pharmaceutical Group Company Limited Announces Executive Changes, Effective April 29, 2024

Full year 2023 earnings released: EPS: CN¥0.55 (vs CN¥0.44 in FY 2022)

Hansoh Pharmaceutical Group Company Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

Now 24% undervalued after recent price drop

Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of HS-10509 Tablets

Now 20% undervalued

Shanghai Hansoh Biomedical Technology Company Limited and Jiangsu Hansoh Pharmaceutical Group Company Limited Receives Clinical Trial Notice

Investor sentiment improves as stock rises 24%

Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of Hs-20106 Injections

Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of "HS-20105"

Upcoming dividend of HK$0.071 per share at 1.4% yield

Hansoh Pharmaceutical Group Company Limited Announces Interim Dividend for the Six Months Ended June 30, 2023, Payable on 28 September 2023

First half 2023 earnings released: EPS: CN¥0.22 (vs CN¥0.22 in 1H 2022)

Hansoh Pharmaceutical Group Company Limited to Report Q2, 2023 Results on Aug 31, 2023

Investor sentiment deteriorates as stock falls 19%

Now 25% undervalued after recent price drop

Hansoh Pharmaceutical Group Company Limited Announces New Drug Application of Ibrexafungerp Tablets Accepted by the National Medical Products Administration

Hansoh Pharmaceutical Group Company Limited Announces HS-10518 Capsules A Category 1 Innovative Drug, Has Been Granted A Clinical Trial Notice

Hansoh Pharmaceutical Group Company Limited Provides Update on Clinical Trial Notice of HS-10516 Capsules

Hansoh (Shanghai) Healthtech Company Limited Obtains an Exclusive License from Biotheus Inc

Upcoming dividend of HK$0.05 per share at 0.7% yield

Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of "HS-10506 Tablets"

Full year 2022 earnings released: EPS: CN¥0.44 (vs CN¥0.46 in FY 2021)

Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Approval of Oral Small Molecule 3CL Protease Inhibitor

Hansoh Pharmaceutical Group Company Limited Announces That " Hs-10390 Tablets " Has Been Granted A Clinical Trial Notice Issued by the National Medical Products Administration of the People's Republic of China

Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of "HS-10502 Tablets"

Hansoh Pharmaceutical Group Company Limited Announces European Medicines Agency Accepts Review of EQRx's Marketing Authorization Application for aumolertinib

Insufficient new directors

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Upcoming dividend of HK$0.05 per share

Hansoh Pharmaceutical Group Company Limited Announces Interim Dividend for the Six Months Ended June 30, 2022, Payable on 30 September 2022

First half 2022 earnings released: EPS: CN¥0.22 (vs CN¥0.22 in 1H 2021)

Hansoh Pharmaceutical Group Company Limited to Report First Half, 2022 Results on Aug 26, 2022

Investor sentiment improved over the past week

Upcoming dividend of HK$0.09 per share

Insufficient new directors

Hansoh Pharmaceutical Group Company Limited Proposes Final Ordinary Dividend for the Financial Year End December 31, 2021, Payable on July 15, 2022

Hansoh Pharmaceutical Group Company Limited Announces New Drug Application for the New Indication of Pegmolesatide Injections

Full year 2021 earnings released: EPS: CN¥0.46 (vs CN¥0.44 in FY 2020)

Full year 2021 earnings released: EPS: CN¥0.46 (vs CN¥0.44 in FY 2020)

Hansoh Pharmaceutical Group Company Limited Announces Final Dividend for the Year Ended December 31, 2021, payable on July 5, 2022